For the first time in its history, Medicare is preparing to cover weight loss drugs at scale. Beginning July 1, 2026, the new Medicare GLP-1 Bridge will give eligible Part D beneficiaries access to medications like Wegovy, Zepbound, and the newly approved Foundayo for a flat $50 monthly copay. The program is being framed as a modest pilot, scheduled to run only through the end of 2027. Yet the financial implications, for both the federal government and the broader insurance market, are anything but modest. What looks like an administrative bridge between two coverage models may turn out to be the moment American health policy fully collides with the cost reality of GLP-1 drugs.
The structure of the program is unusual. Rather than fold GLP-1 weight loss coverage into the existing Part D benefit, the Centers for Medicare and Medicaid Services has built a separate demonstration that operates outside the normal claims process. Pharmacies will route prescriptions through a central processor, collect a $50 copay from the patient, and be reimbursed at no less than the wholesale acquisition cost. Manufacturers have agreed to a negotiated net price of $245 per monthly supply, with the difference between the list price and the negotiated price flowing back to CMS in the form of manufacturer rebates. The result is a tightly controlled pilot that lets the government test demand and gather data before deciding whether to make a longer-term commitment.
That longer-term commitment was supposed to come through a separate initiative known as the BALANCE Model, an effort by the CMS Innovation Center to extend GLP-1 access through state Medicaid programs and eventually shift the cost burden in Medicare onto Part D plan sponsors. Medicaid implementation is moving forward, but the Medicare arm of BALANCE has been indefinitely delayed, which is why the Bridge program had to be extended by a full year. The official explanation is that CMS needs more time to collect utilization data. The unofficial reality is that early estimates suggested the longer-term model would have cost private insurers billions of dollars in its first year alone, and the political appetite to impose that bill turned out to be smaller than the policy plan assumed.
Eligibility is structured to target patients with clear medical need rather than purely cosmetic use. To qualify, beneficiaries must be enrolled in a Part D plan and meet specific clinical criteria. A body mass index of 27 or higher paired with a qualifying condition such as heart disease, hypertension, chronic kidney disease, or prediabetes will open the door. A body mass index of 35 or higher qualifies automatically. People already on a GLP-1 for weight loss can continue treatment under the Bridge as long as their prescriber attests that the original clinical criteria were met at the time therapy began, even if subsequent weight loss has since pushed their BMI lower.
The benefit comes with significant caveats that beneficiaries will need to understand. The $50 copay does not count toward the Part D deductible, nor does it apply to the $2,100 out-of-pocket maximum that takes effect in 2026 and rises to $2,400 in 2027. People who qualify for the low income subsidy, often called Extra Help, cannot use that assistance to reduce the cost of Bridge drugs. For seniors accustomed to paying $5 or $10 for their prescriptions, $50 a month may still represent a meaningful barrier, and over the course of a year the math works out to $600 per beneficiary in direct out-of-pocket spending before any of the government-side costs are counted.
That brings the conversation to the larger budget picture. Medicare already spent roughly $27.5 billion in gross terms on GLP-1 drugs in 2024, before rebates and before any weight loss coverage existed. Those prescriptions were almost entirely for diabetes and cardiovascular indications, where the drugs have long been covered. Adding obesity to the list of approved uses, even through a tightly designed pilot with negotiated pricing, opens the door to a population measured in the tens of millions. Roughly four in ten American adults meet the clinical definition of obesity, and a substantial share of Medicare beneficiaries fall into the BMI and comorbidity ranges that would make them eligible for the Bridge. Even at the negotiated $245 net price, the arithmetic of broad uptake produces numbers that compete with the largest line items in the entire Medicare program.
There is also the question of clinical durability. Most studies of GLP-1 therapy for weight loss have shown that patients who stop the drugs regain a significant portion of the weight they lost while taking them. The Bridge program is designed to end on December 31, 2027, with no firm commitment to a successor program. If hundreds of thousands of beneficiaries start therapy under the demonstration and then lose coverage when it expires, the system will face a predictable wave of patients either paying full price out of pocket, switching to less effective alternatives, or simply discontinuing treatment and regaining weight. None of those outcomes is good for Medicare’s long-term cost trajectory, and all of them complicate the political math for whatever comes next.
For now, the practical takeaway for beneficiaries is straightforward. If you are enrolled in a Part D plan, meet the BMI and comorbidity criteria, and your prescriber is willing to submit a prior authorization request, you will have access to brand-name weight loss medications starting in July at a fraction of the cash price. For policymakers, the takeaway is harder. The Bridge solves a coverage gap that has frustrated patients and clinicians for years, but it does so by deferring rather than resolving the underlying question of who ultimately pays for these drugs at population scale. The pilot will generate the data CMS says it needs. Whether the political system can act on that data once it arrives is a separate question, and one the Bridge program itself was not designed to answer.